Multiple Myeloma

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.

An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.

Agha detailed updated findings from CARTITUDE-2 investigating cilta-cel for previously treated patients with multiple myeloma.

Close monitoring for neurologic toxicity resulted in no long-term effects in a patient cohort treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

After almost 5 years of follow-up, results strongly support upfront daratumumab with lenalidomide and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

Patients with myeloma who received bortezomib, thalidomide, and dexamethasone with autologous stem cell transplant had better response duration when daratumumab was used as maintenance therapy.

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel significantly improved outcomes for patients with relapsed or refractory multiple myeloma when compared with conventional therapies.

Data from the OPTIMUM/MUKNINE trial presented at 2021 EHA Congress show promise for daratumumab plus CVRd as induction in patients with multiple myeloma and certain high-risk disease factors.

The standard of care cohort comprised of patients across 3 global trials acted as a comparator for treatment with cilta-cel in patients with triple-class exposed multiple myeloma.

Further investigation will determine if initial results regarding the use of anakinra as prophylaxis for orvacabtagene autoleucel in multiple myeloma is efficacious enough for use in the real-world setting.

CancerNetwork® sat down with Ola Landgren, MD, PhD, at the 2021 EHA Congress to talk about his presentation on first-line standard of care for multiple myeloma.

Ola Landgren, MD, PhD, looks at results from the phase 2 CARTITUDE-2 trial of ciltacabtagene autoleucel for patients with multiple myeloma and 1 to 3 prior lines of therapy presented at the 2021 ASCO Annual Meeting.

Subcutaneous Elranatamab had high response rates when given at or above 215 μg/kg.

Data from the MonumentTAL-1 trial detailed the benefits with the recommended phase II dose of talquetamab to treat patients with relapsed/refractory multiple myeloma.

Treatment with the off-the-shelf, full-size BCMA X CD3 bi-specific antibody appeared well tolerated with promising efficacy among patients with relapsed/refractory multiple myeloma.

The investigational BCMA-directed CAR T-cell therapy sustained durable responses for heavily pretreated patients with relapsed/refractory multiple myeloma.

Compared to upfront autologous stem cell transplantation for newly diagnosed, transplant-eligible patients with multiple myeloma, carfilzomib consolidation with cyclophosphamide and dexamethasone produced noninferior results.

In a first-in-human study of patients with relapsed or refractory multiple myeloma, the autologous CAR T-cell therapy CART-bbBCMA led to at least a partial response in all treated patients.

CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 2021 ASCO Annual Meeting to talk about updated data from the KarMMa trial of CAR T-cell therapy idecabtagene vicleucel to treat patients with relapsed or refractory multiple myeloma.

When performed with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan, alloHCT was safe in patients with high-risk multiple myeloma.

High rates of durable complete responses are reported at the 2021 ASCO Annual Meeting with ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma.

The CAR T-cell product idecabtagene vicleucel in patients with heavily pretreated multiple myeloma continued to show benefit of therapy at a median follow-up of 24.8 months.

Based on data from a phase 1 trial, the FDA granted breakthrough therapy designation to teclistamab for certain patients with pretreated multiple myeloma.

Based on data from the CARTITUDE-1, the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel moves forward towards regulatory approval in multiple myeloma.

Recently announced phase 3 data show similar progression-free survival results between melflufen and pomalidomide, the most used medicine for patients with relapsed or refractory multiple myeloma.

Kathryn Maples, PharmD, BCOP, discusses real-world implications of belantamab mafodotin in patients with pretreated multiple myeloma.

A clinical pharmacy specialist discusses what’s needed to get the REMS program set up and touches on reimbursement considerations for the administration of belantamab mafodotin in patients with multiple myeloma.

A clinical pharmacy specialist details her experience with the REMS program for administration of belantamab mafodotin in patients with multiple myeloma.

Statistical significance was reached across all end points of the phase 3 GENESIS trial investigating granulocyte colony stimulating factor plus either motixafortide or placebo in patients with multiple myeloma receiving autologous bone marrow transplantation.